Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
Business Wire•15/10/2026•18:45 ET
5
Key Highlights
- ➤Estrella treated first dose-expansion patient with two EB103 infusions three weeks apart
- ➤Two 5 × 10⁶ EB103 T-cell/kg infusions showed no treatment-related serious adverse events through one month
- ➤Dose-escalation high-dose cohort achieved 100% Month 1 complete response rate in evaluable patients
- ➤Nine dose-escalation patients reported no treatment-related serious adverse events, despite mostly high-risk disease
- ➤Phase I expansion data will inform Estrella’s pivotal trial strategy for EB103
Expert Statements
Cheng Liu, PhD, Chief Executive Officer of Estrella Immunopharma
“Administering two full doses of EB103 within three weeks, with no treatment-related serious adverse events observed to date, is an encouraging start to our expansion phase”
Cheng Liu, PhD, Chief Executive Officer of Estrella Immunopharma
“While this is an early result from a single patient, it supports our rationale for evaluating multiple dosing with the goal of potentially delivering deeper responses in the most difficult-to-treat NHL patients, an approach we believe the safety profile observed with EB103 to date allows us to explore.”
Cheng Liu, PhD, Chief Executive Officer of Estrella Immunopharma
“We look forward to enrolling additional patients and to reporting additional efficacy and safety data from the expansion cohort.”
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
Patient received two infusions three weeks apart at the recommended Phase II dose; no treatment-related serious adverse events observed through the first month of follow-up
Get started
Create a free account to read the full story.